EBMT 2025

UKPS Members Gear Up for EBMT 2025

Are you attending the EBMT 2025 Annual Meeting in Florence this year? This prestigious event promises to deliver the latest advancements in hematopoietic cell transplantation and cellular therapies, and we’ve done the hard work for you by scouring the programme for extracorporeal photopheresis (ECP) abstracts.

The European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting is a cornerstone event for healthcare professionals, providing invaluable opportunities for continued professional development, collaboration, and learning. This year, the conference will take place in the beautiful city of Florence, offering not only scientific insights but also a chance to experience the rich cultural heritage of the region.

We’ve compiled a comprehensive summary of the key ECP and photopheresis presentations, posters, and industry symposiums to ensure you stay updated with cutting-edge research and clinical developments. From emerging treatment protocols to patient outcomes and innovative technologies, these sessions are a must-see for anyone involved in the field.

We hope all of our UKPS members have a wonderful time at the meeting, taking the opportunity to engage with international experts, explore the latest research, and enhance clinical practice in ECP therapy.

Stay tuned for further updates, and we wish all UKPS members a fantastic and informative experience at EBMT 2025!

Sunday, March 30, 08:30 – 18:00 | ePoster Area

086 EXTRACORPOREAL PHOTOPHERESIS TREATMENT IN PEDIATRIC PATIENTS WITH GVHD: INSIGHTS FROM A CASE SERIES
Marina Rierola^1,2, Verónica Pons^1,2, Júlia Ayats^1,2, Mercé Albert^1,2, Sofia Alonso^1,2, Anna Saez¹, Paula Armero¹, Alba Acedo^1,2, Gracia Isis Aguilera^1,2, Isabel Amaya^1,2, Maria Teresa Contijoch^1,2, David Gómez-Vives^1,2, Marta Guerrero^1,2, Carmen Montanero^1,2, Juan Manuel Porras^1,2, Esperanza Ribas^1,2, Marc Vilches^1,2, Laura Alonso³, M Luz Uria-Oficialdegui³, Cristina Díaz de Heredia³, Rafael Parra^1,2
1Blood and Tissue Bank of Catalonia – University Hospital Vall d’Hebron, Barcelona, Spain, ²Transfusional Medicine Group – VHIR, Barcelona, Spain, ³Pediatric Oncology and Hematology – University Hospital Vall d’Hebron, Barcelona, Spain.

P112 TREATMENT OF ACUTE AND CHRONIC GVHD WITH EXTRACORPOREAL PHOTOPHERESIS (ECP): EVIDENCE-BASED RECOMMENDATIONS BY THE ITALIAN SOCIETY OF HEMAPHERESIS AND CELL MANIPULATION (SIDEM)
Monia Marchetti¹, Anna Colpo², Maria Teresa Lupo Stanghellini³, Irene Bianco⁴, Fabio Cruciani⁵, Francesco Ipsevich⁶, Mauro Montanari⁷, Massimo Martino⁸, Angelo Ostuni^9
1Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, ²Azienda Ospedale Università di Padova, Padova, Italy, ³IRCCS Ospedale San Raffaele, Milano, Italy, ⁴U.O. Medicina Trasfusionale e Biologia dei Trapianti Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, ⁵IRCCS San Martino, Genova, Italy, ⁶Camillo-Forlanini Hospital, Rome, Italy, ⁷Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, ⁸GITMO, Reggio Calabria, Italy, ⁹SIDEM, Bari, Italy.

P117 THE IMPACT OF EXTRACORPOREAL PHOTOPHERESIS AND RUXOLITINIB ON THE OUTCOME OF CHRONIC GVHD: A RETROSPECTIVE REAL LIFE ANALYSIS
Salvatore Leotta¹, Alessandra Cupri¹, Gabriella Santuccio¹, Elvira Scalisi¹, Paola De Luca¹, Gaia Stanzione¹, Alessandro Petronaci¹, Miriana Limoli¹, Elisa Mauro¹, Maria Grazia Camuglia¹, Andrea Spadaro¹, Francesco Indelicato², Paolo Spina², Eleonora Spina², Maria Pia Azzaro¹, Nella Toscano¹, Gaetano Moschetti³, Giulio Antonio Milone¹, Giuseppe Milone^1
1Divisione di Ematologia con Trapianto di Midollo Osseo – Policlinico Universitario “G- Rodolico – San Marco”, Catania, Italy, ²Servizio di Immunoematologia e Trasfusionale – Policlinico Universitario “G- Rodolico – San Marco”, Catania, Italy, ³Istituto Oncologico del Mediterraneo, Viagrande, Italy.

P118 EXTRACORPOREAL PHOTOPHERESIS FOR ACUTE AND CHRONIC GVHD IN PEDIATRIC HCTS RECIPIENTS: INSIGHTS FROM KING HUSSEIN CANCER CENTER
Rawad Rihani¹, Shrouq Amer¹, Amira Chakroun², Mayada Abu Shanap¹, Hasan Hashem^1
1King Hussein Cancer Center, Amman, Jordan, ²MEALIS Middle East Life Science, Istanbul, Turkey.

P130 EXTRACORPORAL PHOTOPHERESIS (ECP) IN STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): EFFICACY AND SAFETY PROFILE.
Roberto Maggi¹, Luca Di Marino¹, Ilaria Pansini¹, Sabrina Giammarco², Nicola Piccirillo^1,2, Elisabetta Metafuni², Rossana Putzulu², Maria Assunta Limongiello², Giuseppina Massini², Federica Fatone², Luciana Teofili^1,2, Simona Sica^1,2, Patrizia Chiusolo^1,2
1Università Cattolica del Sacro Cuore, Rome, Italy, ²Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Tuesday, April 1, 18:00 – 19:00 | Firenze (S1): Breaks, Printed Poster

B086 EXTRACORPOREAL PHOTOPHERESIS TREATMENT IN PEDIATRIC PATIENTS WITH GVHD: INSIGHTS FROM A CASE SERIES

Marina Rierola^1,2, Verónica Pons^1,2, Júlia Ayats^1,2, Mercé Albert^1,2, Sofia Alonso^1,2, Anna Saez¹, Paula Armero¹, Alba Acedo^1,2, Gracia Isis Aguilera^1,2, Isabel Amaya^1,2, Maria Teresa Contijoch^1,2, David Gómez-Vives^1,2, Marta Guerrero^1,2, Carmen Montanero^1,2, Juan Manuel Porras^1,2, Esperanza Ribas^1,2, Marc Vilches^1,2, Laura Alonso³, M Luz Uria-Oficialdegui³, Cristina Díaz de Heredia³, Rafael Parra^1,2
1Blood and Tissue Bank of Catalonia – University Hospital Vall d’Hebron, Barcelona, Spain, ²Transfusional Medicine Group – VHIR, Barcelona, Spain, ³Pediatric Oncology and Hematology – University Hospital Vall d’Hebron, Barcelona, Spain

Sunday, March 30, 12:30 – 13:30 | Botticelli (S-1): Industry Symposium

IS11 Delivering Therakos ECP: Best Practice in 2025| THERAKOS

IS11-2 Best practices for nurses – Venous access options for ECP

Speaker: Nina Worel (Vienna, Austria)

Sunday, March 30, 16:30 – 18:00 | Roma (S1): Industry Symposium

IS16 Therakos ECP: A Backbone for GvHD Therapy | THERAKOS

IS16-3 Evidence for treatment of chronic GvHD using ECP – A future backbone for GvHD Therapy 

Speaker: Zachariah DeFilipp (Boston, United States of America)

IS16-4 ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD – improved long-term outcomes

Speaker: Nicolaus Kröger (Hamburg, Germany)

Tuesday, April 1, 14:30 – 15:45 | Leonardo (S-1): How do I… ?

HDI4 How do I … evolve GVHD treatment strategies for unique cases? A focus on ECP | Supported through an unrestricted educational grant by Therakos

HDI4-1 ECP-ruxolitinib combination treatment for refractory severe cGVHD

Speaker: Attilio Olivieri (Ancona, Italy)

HDI4-2 ECP positioning in the treatment algorithm for GvHD in 2025

Speaker: Daniel Wolff (Regensburg, Germany)

Note: Abstracts are under embargo until 17 March 2025.